Logo image of CERS

CERUS CORP (CERS) Stock Fundamental Analysis

NASDAQ:CERS - Nasdaq - US1570851014 - Common Stock - Currency: USD

1.355  +0.02 (+1.88%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CERS. CERS was compared to 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CERS have multiple concerns. CERS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CERS had negative earnings in the past year.
In the past year CERS had a positive cash flow from operations.
In the past 5 years CERS always reported negative net income.
In the past 5 years CERS reported 4 times negative operating cash flow.
CERS Yearly Net Income VS EBIT VS OCF VS FCFCERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

CERS has a better Return On Assets (-9.16%) than 62.03% of its industry peers.
With a Return On Equity value of -34.14%, CERS perfoms like the industry average, outperforming 52.94% of the companies in the same industry.
Industry RankSector Rank
ROA -9.16%
ROE -34.14%
ROIC N/A
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
CERS Yearly ROA, ROE, ROICCERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 60.60%, CERS is in line with its industry, outperforming 59.89% of the companies in the same industry.
CERS's Gross Margin has been stable in the last couple of years.
CERS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
CERS Yearly Profit, Operating, Gross MarginsCERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CERS has more shares outstanding
CERS has more shares outstanding than it did 5 years ago.
CERS has a worse debt/assets ratio than last year.
CERS Yearly Shares OutstandingCERS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CERS Yearly Total Debt VS Total AssetsCERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -4.92, we must say that CERS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.92, CERS is not doing good in the industry: 71.66% of the companies in the same industry are doing better.
CERS has a debt to FCF ratio of 12.67. This is a negative value and a sign of low solvency as CERS would need 12.67 years to pay back of all of its debts.
CERS has a Debt to FCF ratio of 12.67. This is in the better half of the industry: CERS outperforms 73.80% of its industry peers.
CERS has a Debt/Equity ratio of 1.17. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.17, CERS is not doing good in the industry: 80.75% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.17
Debt/FCF 12.67
Altman-Z -4.92
ROIC/WACCN/A
WACC9.04%
CERS Yearly LT Debt VS Equity VS FCFCERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

CERS has a Current Ratio of 2.32. This indicates that CERS is financially healthy and has no problem in meeting its short term obligations.
CERS has a Current ratio (2.32) which is comparable to the rest of the industry.
A Quick Ratio of 1.63 indicates that CERS should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.63, CERS is in line with its industry, outperforming 45.45% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.32
Quick Ratio 1.63
CERS Yearly Current Assets VS Current LiabilitesCERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

CERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.33%, which is quite impressive.
The Revenue has been growing slightly by 7.86% in the past year.
The Revenue has been growing by 16.50% on average over the past years. This is quite good.
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)7.86%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%12.7%

3.2 Future

Based on estimates for the next years, CERS will show a small growth in Earnings Per Share. The EPS will grow by 5.24% on average per year.
CERS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.19% yearly.
EPS Next Y2.64%
EPS Next 2Y23.95%
EPS Next 3Y5.24%
EPS Next 5YN/A
Revenue Next Year20.28%
Revenue Next 2Y17.89%
Revenue Next 3Y9.19%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CERS Yearly Revenue VS EstimatesCERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
CERS Yearly EPS VS EstimatesCERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CERS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CERS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERS Price Earnings VS Forward Price EarningsCERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CERS is valued a bit cheaper than the industry average as 78.07% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 38.63
EV/EBITDA N/A
CERS Per share dataCERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.95%
EPS Next 3Y5.24%

More info and screens

0

5. Dividend

5.1 Amount

CERS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERUS CORP

NASDAQ:CERS (7/30/2025, 11:20:57 AM)

1.355

+0.02 (+1.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners74.53%
Inst Owner Change-0.68%
Ins Owners3.15%
Ins Owner Change20.57%
Market Cap259.02M
Analysts80
Price Target4.76 (251.29%)
Short Float %4.05%
Short Ratio6.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.31%
Min EPS beat(2)6.63%
Max EPS beat(2)15.99%
EPS beat(4)4
Avg EPS beat(4)20.93%
Min EPS beat(4)6.63%
Max EPS beat(4)34.64%
EPS beat(8)6
Avg EPS beat(8)22.1%
EPS beat(12)8
Avg EPS beat(12)11.2%
EPS beat(16)12
Avg EPS beat(16)14.16%
Revenue beat(2)1
Avg Revenue beat(2)-7.11%
Min Revenue beat(2)-14.57%
Max Revenue beat(2)0.34%
Revenue beat(4)1
Avg Revenue beat(4)-5.41%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)0.34%
Revenue beat(8)1
Avg Revenue beat(8)-7.22%
Revenue beat(12)4
Avg Revenue beat(12)-4.31%
Revenue beat(16)8
Avg Revenue beat(16)0%
PT rev (1m)0%
PT rev (3m)16.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.67%
Revenue NY rev (1m)-3.18%
Revenue NY rev (3m)-3.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.25
P/FCF 38.63
P/OCF 30.27
P/B 4.67
P/tB 4.78
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)0.04
FCFY2.59%
OCF(TTM)0.04
OCFY3.3%
SpS1.08
BVpS0.29
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.16%
ROE -34.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.6%
FCFM 3.24%
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
F-Score4
Asset Turnover1
Health
Industry RankSector Rank
Debt/Equity 1.17
Debt/FCF 12.67
Debt/EBITDA N/A
Cap/Depr 120.84%
Cap/Sales 0.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.32
Quick Ratio 1.63
Altman-Z -4.92
F-Score4
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)132.31%
Cap/Depr(5y)95.58%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y2.64%
EPS Next 2Y23.95%
EPS Next 3Y5.24%
EPS Next 5YN/A
Revenue 1Y (TTM)7.86%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%12.7%
Revenue Next Year20.28%
Revenue Next 2Y17.89%
Revenue Next 3Y9.19%
Revenue Next 5YN/A
EBIT growth 1Y39.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year170.67%
EBIT Next 3Y60.42%
EBIT Next 5YN/A
FCF growth 1Y141.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y167.58%
OCF growth 3YN/A
OCF growth 5YN/A